<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928074/" ref="ordinalpos=675&amp;ncbi_uid=5824990&amp;link_uid=PMC3928074" image-link="/pmc/articles/PMC3928074/figure/F1/" class="imagepopup">Figure 1. VEGF <span class="highlight" style="background-color:">Pathway</span> in CLL.  From: Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). </a></div><br /><div class="p4l_captionBody">Figure shows scheme of VEGF receptor signaling pathway in CLL as well as aspects of pathway targeted by bevacizumab, AZD2171, and sunitinib malate.</div></div>